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Do Quality of Life (QOL) Index Scores Truly Reflect the Degree of
Clinical Improvement Following Intervention in Patients With Inter-
mittent Claudication due to Femoro-Popliteal Disease? Results of an
Observational Study
Fayyaz A K Mazari, Mohd N A Abdul Rahman, Tapan Mehta, Peter
McCollum, Ian C Chetter. Academic Vascular Surgery Unit, University of
Hull, Hull, United Kingdom
Objectives:To establish the relationship between quality of life (QOL)
index scores and clinical indicators of lower limbs ischaemia.
Methods: 178 patients (108 men, median age 70 years) with angio-
plastiable femoro-popliteal were recruited. Assessments were done prior to
and at 1, 3 6 and 12 months following intervention(angioplasty and / or
supervised exercise programme). Clinical indicators of lower limb ischaemia
(treadmill walking distances, ankle pressures), generic (SF36, EuroQol) and
disease specific (Kings College VascuQol) quality of life questionnaires were
analysed. Correlation analysis was performed for index scores as well as
individual domain scores using non-parametric tests.
Results: All clinical indicators of lower limb ischaemia and quality of life
index scores showed a statistically significant improvement as result of interven-
tion (Friedman test, p0.005). All generic QOL index scores (SF36, Euro-
Qol) showed moderate but statistically significant correlation with treadmill
walking distances (Spearman rank correlation, r0.523, p 0.005) and
weak but significant correlation to resting ankle brachial pressure index
(r0.153, p0.005). No significant correlation was seen between post
exercise ABPI and generic QOL index scores (r0.033, p0.547). Disease
specific QOL index scores showed similar moderate correlation to the
treadmill walking distances (r0.584, p0.005) and a weak but statistically
significant correlation with resting and post exercise ABPI (r0.378, p 
0.05). All domains of SF36 showed similar results with strongest correlation
seen in the domains of physical function (r 0.538, p0.005) and bodily
pain (r0.524, p0.005).
Conclusion: All generic and disease specific QOL scores show statis-
tically significant improvement with intervention in patients with femoro-
popliteal claudication. However, the degree of improvement seen in clinical
indicators of lower limb ischaemia shows a weak correlation to these scores-
.Therefore, a combination of clinical and QOL indicators should be used to
report outcome for intervention studies in these patients.
Author Disclosures: F.A.K. Mazari, None; M.N.A. Abdul Rahman,
None; T. Mehta, None; P. McCollum, None; I.C. Chetter, None.
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Office-Based Outpatient Angiosuites: A Paradigm for a Safe, Effective,
and Efficient Endovascular Practice
Samuel SAhn1, Julia FChen1,2, KennethRKollmeyer2, Rhoda FLeichter1, Todd
Reil1, Craig Ferrera2, Pablo Uceda2, Christopher Kim1, Kevin Peng1. 1University
Vascular Associates, Los Angeles, CA; 2DFWVascular Group, Dallas, TX
Purpose: To demonstrate that therapeutic and diagnostic endovascu-
lar procedures, traditionally performed in an outpatient hospital setting, can
be done with equal or better safety, efficacy and efficiency in an office setting.
Method: From April 25, 2006 to October 31, 2008, we performed
422 endovascular procedures in our office-based outpatient angiosuite. This
represents 28.3% of total patients who underwent endovascular procedures
in both the hospital and office. There were 213 (50.47%) men and 209
(49.52%) women, with an average age of 60.85 years (range: 17 to 93; SD:
15.89 years). Risk factors included arrhythmia (n21, 4.98%), coronary
artery disease (n108, 25.59%), congestive heart failure (n24, 5.69%),
diabetes (n165, 39.10%), dialysis (n78, 18.48%), hyperlipidemia (n94,
(22.27%), hypertension (n272, 64.45%), COPD (n23, 5.45%), TIA/
CVA (n23, 5.45%), and history ofMI (n47, 11.14%). ASA classifications
were I (n34, 8.05%), II (n73, 17.30%), III (n238, 56.40%), and IV
(n60, 14.22%), with 17 (4.03%) unavailable.
Results: We performed 134 (31.75%) diagnostic angiograms, 204
(48.34%) balloon angioplasties, 72 (17.06%) angioplasties with stent place-
ments, and 6 (1.42%) coil embolizations. All procedures were performed
under local anesthesia with anesthesia standby. The planned procedures
were completed in 97.87% (n413) patients. The complication rate was
2.13% (n9). Of these, 6 were electively admitted (2 thromboemboli, 2
hematomas, 1 malignant hypertension, 1 neuroangio edema) and 1 required
emergency transfer. The reason for transfer was a torn common femoral vein
upon attempted retrieval of a migrated stent. 30-day mortality was 0.46%
(n2), both unrelated to the procedures.
Conclusion: With careful patient selection and technique, therapeutic
and diagnostic endovascular procedures can be safely, effectively, and effi-
ciently performed in an office setting.Author Disclosures: S.S. Ahn, Vascular Management Associates; J.F.
Chen, Vascular Management Associates; K.R. Kollmeyer, None; R.F.
Leichter, None; T. Reil, None; C. Ferrera, None; P. Uceda, None; C.
Kim, None; K. Peng, Vascular Management Associates.
PP95.
Factors Associated with Aspirin-Insensitive Thromboxane Generation
in Patients with Atherosclerosis
Susanna M Nazarian1, Jason B Thompson1, Tyler J Gluckman1, Katherine
Laws1, F Jon Geske2, Steven P Schulman1, Thomas S Kickler1, Jeffrey J
Rade1. 1Johns Hopkins University, Baltimore, MD; 2Corgenix Medical
Corporation, Broomfield, CO
Objective: Measurement of the thromboxane A2 metabolite, 11-
dehydro-thromboxane B2 (TXB2), is used to assess response to aspirin
therapy and to define patients who are “aspirin resistant.” Little is known
about factors that may contribute to persistent TXB2 generation in spite of
adequate suppression of platelet COX-1 activity by aspirin.
Methods: 284 subjects with confirmed inhibition of arachidonic acid
(AA)-induced platelet aggregation by chronic aspirin therapy were tested for
urine TXB2. All patients had undergone CABG 6 months previous. Simul-
taneous hematologic (complete blood count, reticulated platelet count,
ABO blood group,) inflammatory (C-reactive protein, fibrinogen, von
Willebrand factor) and oxidative stress measurements (urine 8-iso prosta-
glandin F2) were performed. Demographic, medical history and pharma-
cological factors were also considered. A multivariate model was created to
predict odds of urinary TXB2 400 pg/mg creatinine (Cr).
Results: Despite complete inhibition of AA-induced platelet aggrega-
tion, 95/284 (33.5%) subjects had TXB2  400 pg/mg Cr. Multivariate
analysis identified several factors associated with odds of high TXB2, shown
below in descending order of strength of evidence:
Predictor for urinary TXB2400 pg/mg creatinine Odds ratio P value
Urine 8-iso-prostaglandin F2alpha ( 1072 vs. 
1072 pg/mg creatinine)
3.73 0.000
Race (white vs. non-white) 0.16 0.001
Beta-blocker use 0.28 0.005
Leukocyte count ( 4.5 vs. 4.5 - 11  103/cubic
mm)
0.13 0.008
Gender (female vs. male) 2.66 0.017
History of congestive heart failure 2.98 0.021
Age (per additional year) 1.04 0.027
von Willebrand factor antigen ( 150 vs.  150%) 2.12 0.034
Aspirin dose (325 mg vs. 81 mg) 0.34 0.045
Leukocyte count ( 11 vs. 4.5 - 11  103/cubic
mm)
4.04 0.346
Conclusions: Persistent thromboxane generation occurs in a substan-
tial percentage of patients 6 months after surgery despite suppression of
platelet COX-1 activity by aspirin. Non-white race, female gender, advanced
age and heart failure appear to be important patient-specific factors associ-
ated with increased aspirin-insensitive thromboxane generation. In addition,
elevated urine thromboxane levels were significantly associated with beta-
blocker use and degree of oxidative stress and inflammation. These latter
findings suggest that metabolism of arachidonic acid via non-enzymatic
and/or COX-2-mediated pathways may be important contributors to aspi-
rin-insensitive thromboxane generation.
Author Disclosures: S.M. Nazarian, None; J.B. Thompson, None; T.J.
Gluckman, None; K. Laws, None; F.J. Geske, Corgenix Medical Corpo-
ration; S.P. Schulman, None; T.S. Kickler, Corgenix Medical Corpora-
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Patterns of Procedure Specific Radiation Exposure in the Endovascular
Era: Impetus for Further Innovation
Mohsen Bannazadeh1, Timur P Sarac1, Ozcan Altinel2, Vikram Kashyap1,
Daniel Clair1. 1The Cleveland Clinic Foundation, Cleveland, OH; 2Univer-
sity of Ankara Turkey, Cleveland, OH
Objective: While patient preference and outcome data support contin-
ued development and utilization of minimally invasive endovascular thera-
pies, only a few studies have documented radiation exposure to the patient.
This report summarizes our patient’s radiation exposure per endovascular
procedure.
